Company intelligence / Profile preview

Zor Pharmaceuticals

Montreal, Quebec, Canada

Ownership: Private
Development stage: Other

Overview

Zor Pharmaceuticals is a specialty pharmaceutical company originally established as a joint venture between Knight Therapeutics and Medison Pharma. The company was formed to commercialize tildrakizumab, a monoclonal antibody targeting the IL-23p19 subunit, in the Canadian and Israeli markets under an exclusive license from Sun Pharmaceutical Industries. Following its formation, Knight Therapeutics acquired the remaining interest in the venture, making Zor Pharmaceuticals a wholly-owned subsidiary. The company's primary focus has been the regulatory approval and commercialization of tildrakizumab (marketed as Ilumya) for the treatment of moderate-to-severe plaque psoriasis.

Therapeutic areas: Dermatology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Sun Pharmaceutical Industries

Beyond the preview

Go deeper on Zor Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zor Pharmaceuticals.

Explore the full profile